Daihan Pharmaceutical Coltd Stock Beta
| 023910 Stock | KRW 26,200 200.00 0.77% |
Daihan Pharmaceutical CoLtd fundamentals help investors to digest information that contributes to Daihan Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Daihan Stock. The fundamental analysis module provides a way to measure Daihan Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Daihan Pharmaceutical stock.
Daihan |
Daihan Pharmaceutical CoLtd Company Beta Analysis
Daihan Pharmaceutical's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Daihan Pharmaceutical Beta | 0.53 |
Most of Daihan Pharmaceutical's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Daihan Pharmaceutical CoLtd is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Daihan Pharmaceutical CoLtd has a Beta of 0.5329. This is 38.03% lower than that of the Healthcare sector and significantly higher than that of the Pharmaceuticals industry. The beta for all Republic of Korea stocks is notably lower than that of the firm.
Daihan Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Daihan Pharmaceutical's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Daihan Pharmaceutical could also be used in its relative valuation, which is a method of valuing Daihan Pharmaceutical by comparing valuation metrics of similar companies.Daihan Pharmaceutical is rated second in beta category among its peers.
As returns on the market increase, Daihan Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Daihan Pharmaceutical is expected to be smaller as well.
Daihan Fundamentals
| Return On Equity | 12.49 | |||
| Return On Asset | 0.0677 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 148.23 B | |||
| Shares Outstanding | 6 M | |||
| Shares Owned By Insiders | 34.84 % | |||
| Shares Owned By Institutions | 13.66 % | |||
| Price To Earning | 11.74 X | |||
| Price To Sales | 0.93 X | |||
| Revenue | 171.46 B | |||
| Gross Profit | 56.19 B | |||
| EBITDA | 39.72 B | |||
| Net Income | 22.67 B | |||
| Cash And Equivalents | 83.73 B | |||
| Total Debt | 14 B | |||
| Debt To Equity | 0.15 % | |||
| Current Ratio | 3.12 X | |||
| Cash Flow From Operations | 40.62 B | |||
| Target Price | 58000.0 | |||
| Beta | 0.53 | |||
| Market Capitalization | 182.1 B | |||
| Total Asset | 272.54 B | |||
| Retained Earnings | 67.17 B | |||
| Working Capital | 33.04 B | |||
| Current Asset | 75.05 B | |||
| Current Liabilities | 42.01 B | |||
| Z Score | 7.8 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 272.54 B |
About Daihan Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Daihan Pharmaceutical CoLtd's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Daihan Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Daihan Pharmaceutical CoLtd based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Daihan Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Daihan Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Daihan Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving together with Daihan Stock
Moving against Daihan Stock
The ability to find closely correlated positions to Daihan Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Daihan Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Daihan Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Daihan Pharmaceutical CoLtd to buy it.
The correlation of Daihan Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Daihan Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Daihan Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Daihan Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Daihan Stock
Daihan Pharmaceutical financial ratios help investors to determine whether Daihan Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Daihan with respect to the benefits of owning Daihan Pharmaceutical security.